EyePoint shares plummeted more than 84% Monday morning after the company announced that its phase 3 Lucia trial—its final holdout in wet age-related macular degeneration (wet AMD) following a previ | ...

Age-related macular degeneration (AMD) affects more than 5 million people around the world. And until now, no treatment could ...

EyePoint stock crashed 85% after Duravyu missed a Phase 3 wet AMD endpoint. Click here to read my most recent analysis of ...

The Meta Quest 3 can handle a lot of tasks from productivity to gaming, but how does it stack up against other AMD GPUs you ...

EyePoint, Inc. (NASDAQ:EYPT) announced plans to reduce its workforce by approximately 53% and conclude its pivotal Phase 3 ...

LUCIA did not achieve the primary endpoint of statistical non-inferiority in mean change in BCVA versus on-label aflibercept control, despite demonstrating visual improvement- ...

AMD’s $8.2B World Labs acquisition signals a major AI talent play to fuel the next AI frontier. Click for more on AMD stock.

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The acquisition will see World Labs founder Fei-Fei Li join AMD as executive vice president and chief scientist.

AMD launches Versal AI Edge Series Gen 2, combining AI inference, sensor processing, and embedded compute in a single chip for edge applications.

EyePoint on Monday said it would cut about 53% of its workforce and stop studies of ​its experimental eye drug for an ‌age-related vision disease after it failed a second late-stage trial. Here are ...